Clinical Trial

Lenvatinib for Advanced Bone and Soft Tissue Sarcoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A total of 60 patients with metastatic/surgically unresectable bone and soft tissue sarcomas who had previously received multi-target TKI therapy and failed were enrolled to evaluate the efficacy and safety.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-11-14; most recent amendment 2023-08-17.
Status change: Not Yet Recruiting → Recruiting 2023-08-17
Trial Details
NCT Number NCT05617859
Lead Sponsor Henan Cancer Hospital
Conditions Effectiveness, Sexuality
Enrollment 60 participants
Start Date 2023-04-30
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-08-21